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Summary 
The frequency of mutant T cells (FMC) in blood lymphocytes from patients with systemic hpus 
erythematosus  (SLE)  was measured by growing  cells  in  the  presence  and  in  the  absence of 
6-thioguanine.  Patients with SLE had a spectrum of FMC ranging  from normal to about 100 
times normal.  This high  FMC among calls  from SLE patients  appears to reflect excessive  in 
vivo  activation  and  proliferation  during  the  course  of the  disease.  This  represents  the  first 
demonstration of such a T  cell abnormality in SLE; it supports the hypothesis that SLE T cells 
demonstrate  increased in vivo division and/or  survival. 
H 
uman systemic lupus erythematosus (SLE) is an autoimo 
mune disease that exhibits a characteristic spectrum of 
autoantibodies reactive with DNA, histones, various smaller 
nucleoproteins,  cytoplasmic proteins,  and cell surface com- 
ponents of lymphocytes agd red blood cells (1). This inten- 
sive autoantibody production is associated with both poly- 
donal B cell activity and oligodonal expansion of sdective 
populations of antibody-forming calls (2). It is thought that 
T  lymphocytes play a role in both processes, but are critical 
in  the latter  (2-5). 
The  hprt gene  encodes  the  salvage  pathway  enzyme, 
hypoxanthine-guanine phosphoribosyl transferase.  If a T cell 
sustains a mutation in hprt that reduces or abolishes hprt ac- 
tivity, the cell can be clonally selected in vitro (6, 7), since 
hprr  cells are able to grow in the presence of the purine 
analogue 6-thioguanine  (6-TG).  By comparing the growth 
of T  calls in the presence and in the absence of 6-TG,  it is 
possible to measure in vivo mutant frequencies of T cells and 
to isolate cells reactive with putative stir-antigens  from the 
mutant  fraction  (8). 
The rationale for using 6-TG to detect in vivo T cell muta- 
tions in autoimmune disease is based upon certain assump- 
tions.  (a) During the course of disease,  a fraction of the T 
lymphocytes (either oligoclonal or polyclonal) will be acti- 
vated to proliferate; (b) random spontaneous mutations occur 
more frequently in proliferating than resting T cells; and (c) 
measurement  of mutations in the hprt gene allows an esti- 
mate of the in vivo frequency of mutant T  cells  (FMC) as 
a crude indicator  of past T  cell proliferation. 
Others have optimized and characterized this analysis  of 
FMC (9,  10),  and it has been used to demonstrate myelin 
basic protein-reactive  T  ceUs in multiple  sclerosis  (8).  We 
chose to use it in the assessment of self-antigen-reactive T 
calls  in  SLE.  However, before studying  responses  to  self- 
antigens,  we observed that  many more lupus than  normal 
T  call clones grew in the presence of 6-TG.  That  led to a 
formal analysis  of the phenomenon and the present report. 
Materials  and Methods 
Subjects.  We studied 18 patients with SLE (11), nine normal 
individuals, and three patients with arthritis  without lupus (two 
with rheumatoid arthritis and one with psoriatic arthritis). Normal 
individuals were blood bank donors at the Clinical Center (NIH). 
As a positive assay control,  we studied two patients with partial 
hprt deficiency. 
Cell Culture.  Mononuclear cells (MNC) from the blood of pa- 
tients and normals were isolated by Ficoll-Hypaque centrifugation 
and T cells were cultured  to establish the fraction of hprr  mu- 
tants essentially as described (9). Medium consisted, by volume, 
of 55% RPM11640 (Biofluids, Rockville, MD) containing 50 U/m1 
penicillin,  50/~g/ml streptomycin,  and 2 mM L-glutamine, 5% 
FCS (Biofluids), 20% HL-1 medium (Ventrex, Portland, ME), and 
20% lymphokine-activated  killer (LAK) cell supematant  (12) as 
a source of IL-2, and other lymphokines (kindly provided by J. R. 
YanneUi, NCI, NIH). The culture medium contained 0.25/~g/ml 
PHA (Burroughs-Wellcome, Greenville, NC). As feeder cells, ir- 
radiated (90 Gy, from a 137Cs source) Tk 6 cells were added (ob- 
tained from Dr. J. P. O'Neill, Genetics Laboratory, University of 
Vermont,  Burlington,  VT). For determination  of the total lym- 
phocyte cloning efficiency  (CE), cells  were seeded  in round-bottomed 
microtiter  plates (Costar, Cambridge,  MA) at 0.25, 0.5,  1, 2, 4, 
and 8 lymphocytes/weU. Each well also contained 5  x  103 irradi- 
ated Tk  6 cells. Selection of hprt- mutants  was performed  by 
seeding 2  x  103 and 2  x  104 lymphocytes per well in the pres- 
ence of 104 irradiated Tk 6 cells and 10-s M 6-thioguanine  (2- 
amino-6-mercapto-purine;  Sigma Chemical Co., St. Louis, MO). 
In some patients with high FMC, limiting  dilution  experiments 
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Figure 1.  Representative  limit- 
ing dilution experiment of a pa- 
tient's T cells grown in the absence 
of  6-TG. The cloning  eflidency  for 
this patient was 35%. 
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Figure 2.  Growth ofT cells in 
the presence of 6-TG. Far fewer 
cells grew in the presence of  6-TG. 
Nevertheless, a comparable log- 
linear relationship was found in 
limiting dilution studies. 
were also carried  out under 6-TG-selective pressure.  For each cell 
concentration, at least two microtiter plates were set up for cul- 
tures without 6-TG and at least four for cultures with 6-TG. The 
cultures  were incubated in 5-6% CO2 in air, at 37~  for 11-14 d, 
and subsequently inspected  using an invertoscope.  65 consecutive 
clones were studied for cell surface phenotypes; all were T  lym- 
phocytes. 
Evaluation of Lymphocyte Outgrowth.  Under the assumption of 
a Poisson distribution of  clonable cells in limiting dilution studies, 
the FMC was established  by dividing the apparent frequency of 
6-TG-resistant calls by the CE, as follows: FMC  =  [-In (fraction 
of negative wells in the presence  of 6-TG)/no.  lymphocytes per 
well]/CE. CE  =  [-ln (fraction of negative  wells in the absence 
of 6-TG)/no.  lymphocytes per well]. 
Results 
Cells from patients and controls were cultured at limiting 
dilution in the presence and absence of 6-TG. It was deter- 
mined that there was a log-linear relationship  between cell 
input and fraction of negative wells: all showed a good linear 
Table  1.  Age, Gender, and Therapy of SLE Patients Studied 
Patient  Age  Gender  Race  Current  Rx  Past  Rx  FMC 
1  42  F  W  PR,  PL, AZ  PR,  PL, AZ  10,753 
2  49  F  W  MED, CY,  PL  PR  1,650 
3  21  F  W  MED,  CY  PR,  AZ (3)  1,379 
4  37  F  W  PR  PR,  PL  1,200 
5  41  F  W  PR,  PL  PR,  PL  1,090 
6  60  M  W  PR,  AZ  PR,  AZ, CY  1,086 
7  32  F  W  MED,  CY  PR  655 
8  24  F  W  PR  PR,  PL  647 
9  26  F  B  PR,  CY  PR,  PL  124 
10  33  F  B  PR,  CY  PR  92 
11  46  F  W  MED  PR  81 
12  33  F  W  PR  MED  69 
13  30  F  W  PR  PR,  AZ (3)  42 
14  41  F  W  MED,  CY  PR,  PL  41 
15  40  M  B  PR  PR  31 
16  39  F  W  PR  PR,  AZ (11)  25 
17  31  F  B  MED  PR  24 
18  16  F  W  PR  PR  19 
PR, prednisone; MED, medrol; CY, Cyclophosphamide;  PL, hydroxychloroquine; AZ, Azathioprine. Numbers in parentheses indicate years since 
last dose. Controls: 6 F and 3 M, with age range of 23-57 yr and mean age the same as that of the patients. 
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Figure  3.  The  apparent  fre- 
quencies of mutant T  cells are 
shown for nine normal controls, 
three patients with arthritis (two 
with rheumatoid arthritis and one 
with psoriatic arthritis),  and 18 
patients  with  systemic  lupus. 
More than half of the lupus pa- 
tients  were  >3  SD  above the 
highest  normal  control.  Also 
shown are two males with defects 
in h/m as positive controls for the 
ability  oft cells to grow in 6-TG. 
relationship comparable with that depicted in Fig. 1. The 
range of calculated cloning eflidencies was 6-90% for normal 
controls and 5-60%  for the patients (data  not shown). 
Simultaneously, similar cultures were set up with 6-TG in 
the medium. As expected, a much lower frequency of clones 
was found. As a result, it was possible to construct formal 
timiting dilution curves only for individuals with a very high 
frequency. In those cases, however, we again observed a log- 
linear relationship, as shown in Fig.  2.  In this individual, 
T cell clone growth for 6-TG-resistant (i.e. hprt-negative) cells 
was 1/4,000 or 250/10+. 
For aU individuals, cultures were established and analyzed 
in medium with and without 6-TG. The results of both cul- 
tures were used to derive an apparent FMC for each individual 
(see Materials  and Methods). The data are summarized in 
Fig. 3. As a group, patients with systemic lupus had substan- 
tially higher FMC than did controls (Fig.  3).  Several SLE 
patients, especially a few with very high FMC, were reevalu- 
ated: the results of repeat studies were quite comparable; how- 
ever, only the data from the original evaluation were used 
to construct Fig.  3. 
It is appropriate to be concerned about the possible con- 
tribution of cytostatic and cytotoxic drugs to the results ob- 
tained. Table 1 gives the information on therapy in individual 
patients. The patient with the highest FMC was receiving 
azathioprine at the time of study. Patient 6 with a high FMC 
also was receiving that drug. Two other patients, nos. 3 and 
13,  had previously received azathioprine, and it had been 
stopped in both 3 yr before study. One had quite a high FMC 
but the FMC of the other was 20-fold less. Several patients 
had received cyclophosphamide; however, there was no ob- 
vious correlation with FMC. The two boys with a (partial) 
genetic defect in the hprt gene had, as expected, a very high 
frequency of cells able to grow in 6-TG; however, it did not 
approach 100%. 
Discussion 
Among 18 patients with SLE studied, several had increased 
FMC as measured by the hprt-mutant sdection system. This 
was not a general feature of lupus patients in that some had 
normal FMC. Those with elevated FMC represented a spec- 
trum from slightly increased to some 2 logs increased. 
It is presumed that SLE patients with devated FMC had 
increased numbers of T calls that had been driven to proliferate, 
thereby causing an increase in random mutations, as has been 
argued previously (8). Of the six patients studied, herein, 
with disease duration of 20 yr,  five had very high FMC 
(>1,000/10  + cells).  It  is  possible  that  some  product  of 
severity and duration ofhpus disease activity might ultimately 
correlate with FMC. However, we believe that a larger number 
of patients would have to be studied serially to determine 
whether or not this relationship is true. 
In theory, the SLE patients with massive T  cell growth 
in the presence of 6-TG could be carriers of a partial defect 
in hprt. We believe that such an explanation does not account 
for the observed growth of SLE T cells in 6-TG because: (a) 
such a carrier frequency would be far greater than expected, 
and (b) the broad range seen among SLE patients might better 
be explained by a variable history of in vivo T cell activation. 
We found no obvious correlation between drug therapy 
and FMC. Although certain drugs potentially could increase 
the FMC, for most drugs, the increase would not be expected 
to be as great as that observed herein, and in some studies 
it has been quite modest (13). One drug, azathioprine, could 
potentially be responsible for some of the devated FMC. This 
drug might both induce mutations and sdect in vivo for 
6-TG-resistant clones. However, only two of the patients were 
receiving azathioprine at the time of study. Three additional 
patients had received azathioprine in the past, two with modest 
and one with a high FMC. Thus, in several patients, high 
FMC appears to be largely independent of drug therapy. 
In this study, we used ceils from two individuals with partial 
defects in hprt to provide a positive assay control for growth 
in 6-TG. Although these individuals demonstrated the greatest 
growth in 6-TG, their FMC was not quite 10%, whereas it 
might have been expected to be closer to 100% if their defect 
in hprt was uniform and severe. This result raises the possi- 
bility that our cloning dticiency in 6-TG was less than we 
assumed, and that the FMC in patients might actually be 
greater than we have calculated. 
T cells of patients with SLE are subject to in vivo activa- 
tion (14), which is thought to stimulate B cells to produce 
antibodies, including autoantibodies (2, 4, 5). Over time, such 
T cell activation would be expected to result in an accumula- 
tion of mutations. By chance, some occur in the hprt gene 
and are detectable in the assay system used herein. It would 
be expected that studies of other genes would also demon- 
strate mutations in SLE T cells. Unfortunately, biochemical 
selection strategies are not readily available for other genes. 
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cessive division and/or prolonged survival ofSLE T calls (in- 
cluding stir-reactive T ceils), evidence supporting such an hy- 
pothesis has been lacking.  The present report,  for the first 
time, demonstrates an increased mutant T  cell frequency in 
many individuals with lupus.  Additional  experiments  will 
assess the mutations in the hprt gene as well as TCR usage 
among the panels of T  cell clones. Such work will provide 
information as to whether the hprt mutant T cells represent 
oligoclonal expansion of only a few progenitors, or, alterna- 
tively, constitute a population  that was substantially poly- 
clonal in origin.  Further  studies will also analyze possible 
skewing of mutant  T  cell clones toward autoreactivity. 
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